Quick Answer: CAR-T for Multiple Myeloma in China, 2026
BCMA CAR-T for relapsed/refractory multiple myeloma in China costs $89,000-$151,000 (commercial) or $30,000-$80,000 (clinical trial) — 65-85% below the two US BCMA products, which list at $437,000-$465,000. China has more NMPA-approved CAR-T products than any other country and is the home of Legend Biotech, the Nanjing company that co-developed Carvykti — the world's leading BCMA CAR-T. Eligible patients are usually treated with no waitlist, with most slots bookable 2-4 weeks after eligibility is confirmed. The full journey, from records review to infusion, takes about 4-6 weeks in China.
1. How Much Does CAR-T for Multiple Myeloma Cost in China? (2026)
Like all CAR-T in China, BCMA therapy has two price tiers. Quotes for the same indication can differ by 3-5x between patients depending on the access route.
| Access Route | 2026 Price (USD) | Best For |
|---|---|---|
| Commercial (NMPA-approved BCMA CAR-T) | $89K – $151K | Patients who want an approved product with no trial eligibility requirements |
| Clinical trial / sponsored access | $30K – $80K | Eligible patients willing to enroll in a hospital- or manufacturer-sponsored trial |
China vs US vs Singapore vs Germany (BCMA CAR-T for Myeloma)
| Country | Commercial Price (USD) | Notes |
|---|---|---|
| China | $89K – $151K | Equecabtagene (Fucaso) and zevor-cel approved; home of Carvykti co-developer Legend Biotech |
| United States | $437K – $465K | Carvykti (ciltacabtagene) and Abecma (idecabtagene) list prices |
| Singapore | $280K – $350K | BCMA CAR-T not yet commercial locally; Kymriah (CD19) available |
| Germany / EU | $320K – $400K | Carvykti and Abecma approved; prices vary by country |
2026 estimates based on published pricing and patient-reported quotes. China's cost advantage comes from domestic manufacturing and lower hospitalization costs. Travel and accommodation are not included in any figure.
Full Trip Budget for International Myeloma Patients
| Item | Estimated Cost (USD) |
|---|---|
| Medical visa + invitation letter | $0 – $140 |
| Round-trip flights (Asia → China) | $400 – $1,500 |
| Hospital deposit (payable on admission) | 30-50% of quoted CAR-T cost |
| Hospital stay (4-6 weeks, incl. monitoring) | Included in CAR-T package |
| Companion accommodation | $1,500 – $4,000 |
| Translator / medical coordinator | $500 – $2,000 |
| Post-treatment follow-up (3, 6, 12 months) | $1,000 – $3,000 |
| Total trip (excluding CAR-T) | $3,500 – $10,500 |
2. Top 4 Hospitals for BCMA CAR-T in Multiple Myeloma
All listed hospitals have dedicated hematology departments with international patient offices and English-speaking coordinators.
1. Ruijin Hospital — Shanghai Jiao Tong University School of Medicine
| Field | Detail |
|---|---|
| Official English name | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
| Specialties | Hematology (#1 in China, Fudan Ranking), CD19 and BCMA CAR-T, CRS management |
| International patient services | Yes — international affairs office, English team, visa invitation letters within 48 hours |
| Cost range | $89K – $130K commercial; trial slots frequently open for relapsed/refractory myeloma |
| Waiting time | 2-4 weeks after eligibility confirmed (commercial); 4-8 weeks (trial) |
| Why recommended | One of the largest CAR-T programs in Asia; published outcomes on 500+ CAR-T patients; on-site GMP-standard cell processing lab |
2. Lu Daopei Hospital — Beijing
| Field | Detail |
|---|---|
| Official English name | Lu Daopei Hospital |
| Specialties | Hematology-only (leukemia, lymphoma, multiple myeloma), BCMA-targeted CAR-T for myeloma |
| International patient services | Yes — patients from 12+ countries, English-speaking case managers, care coordination back to home country |
| Cost range | $100K – $145K commercial |
| Waiting time | 2-4 weeks after eligibility confirmed |
| Why recommended | Founded by a pioneer of bone marrow transplantation in China; exclusive focus on blood cancers; myeloma CAR-T outcomes reported at or above international benchmarks |
3. Fudan University Shanghai Cancer Center — Shanghai
| Field | Detail |
|---|---|
| Official English name | Fudan University Shanghai Cancer Center (Fudan Cancer Hospital) |
| Specialties | Hematologic malignancies, early BCMA CAR-T trials, high-volume cell therapy program |
| International patient services | Yes — dedicated International Patient Center, English/Japanese/Korean/Arabic interpreters, 20+ insurers for direct billing |
| Cost range | $95K – $140K commercial |
| Waiting time | 2-3 weeks; typically the shortest slots among top centers |
| Why recommended | One of the highest-volume CAR-T programs in Asia with 800+ patients treated since 2019; strong clinical-trial pipeline for next-generation BCMA constructs |
4. Tongji Hospital — Huazhong University of Science & Technology
| Field | Detail |
|---|---|
| Official English name | Tongji Hospital, Tongji Medical College, HUST |
| Specialties | Hematologic malignancies (top 10 nationally), high-volume myeloma program |
| International patient services | Yes — English and Russian support |
| Cost range | $75K – $115K commercial — among the most competitive hematologic CAR-T pricing in China |
| Waiting time | 2-4 weeks (commercial) |
| Why recommended | Significantly lower pricing than Tier-1 city hospitals with comparable program volume; a strong option for budget-conscious international patients |
Not sure if your case qualifies? Send the latest bone marrow biopsy and serum free light chain results (within 3 months) plus prior treatment lines — we route your case to the right hematology center within 48 hours and get a written quote back. Get a free hospital recommendation and cost estimate → Start Free Case Review (We reply within 24 hours · 100% confidential · No obligation).
3. Why China for Multiple Myeloma CAR-T?
| Factor | Detail |
|---|---|
| Approved products | 7 NMPA-approved CAR-T products as of mid-2026 — more than the US (6) or EU (5); two are BCMA-targeted for myeloma |
| Home of Carvykti | Carvykti, the world's leading BCMA CAR-T, was co-developed by Nanjing-based Legend Biotech — China is the therapy's origin |
| Cost advantage | 65-85% below US BCMA list prices; 40-60% below Singapore; domestic manufacturing keeps cost down |
| Trial access | 500+ active CAR-T trials globally — the largest pipeline is in China; BCMA trial slots are among the most available |
| No waitlist | Commercial slots book in 2-4 weeks after eligibility; trial enrollment 4-8 weeks |
| Volume | Tier-1 hematology centers perform 200-400+ CAR-T infusions per year — comparable to MD Anderson or Memorial Sloan Kettering |
4. Treatment Timeline: From Contact to Infusion
| Phase | What Happens | Duration |
|---|---|---|
| 1. Records review (free) | Send bone marrow biopsy, serum free light chain, imaging, prior treatment lines | 48 hours |
| 2. Eligibility + quote | Hospital confirms BCMA expression and candidacy; written commercial quote in 7-10 working days; parallel trial options listed | 1-2 weeks |
| 3. Deposit & slot | 30-50% deposit locks the manufacturing slot (commercial); or informed consent for trial | 1 week |
| 4. Visa & travel | Hospital issues medical visa invitation letter; travel to China | 2-4 weeks |
| 5. Apheresis | T-cells collected (1 day outpatient procedure) | Day 1 |
| 6. Manufacturing | CAR-T cells engineered (China domestic: faster turnaround) | 2-4 weeks |
| 7. Conditioning + infusion | 3-5 days lymphodepleting chemo, then 1-day infusion | 1 week |
| 8. Monitoring | Inpatient monitoring for CRS and side effects | 10-14 days |
| 9. Follow-up & return | 30-day medication plan; tele-consults with the China team for the first year | Ongoing |
Total China stay: 4-6 weeks.
5. Real Patient Example
A 61-year-old patient from Southeast Asia with multiple myeloma — relapsed after a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody — was assessed at Lu Daopei Hospital in Beijing. BCMA expression was confirmed from a fresh bone marrow biopsy. He received a commercial BCMA CAR-T, completed apheresis and infusion within five weeks, and was discharged with a 30-day medication plan. Follow-up labs at 3 and 6 months were coordinated between his local hematologist and the Lu Daopei team via tele-consult.
Individual results vary. Outcomes depend on disease biology, prior treatment, and eligibility. A hematologist at the hospital will evaluate your case and recommend the appropriate route. More patient journeys: Maria's case at Shanghai Ninth People's Hospital · David's lung cancer treatment.
6. Frequently Asked Questions
How much does CAR-T therapy for multiple myeloma cost in China in 2026?
Commercial BCMA CAR-T costs $89,000-$151,000 in China; clinical trial access can reduce this to $30,000-$80,000. The two FDA-approved BCMA products in the US list at $437,000-$465,000 (Abecma and Carvykti). (2026 estimates based on published data; final cost depends on product, hospital, and case complexity.)
Which BCMA CAR-T products are approved in China?
China has approved equecabtagene autoleucel (Fucaso) and zevor-cel for relapsed/refractory multiple myeloma. China is also home to Nanjing-based Legend Biotech, co-developer of Carvykti — the world's leading BCMA CAR-T sold globally.
Who is eligible for BCMA CAR-T for multiple myeloma in China?
Most programs target relapsed or refractory myeloma after at least three prior lines, typically including a proteasome inhibitor and an immunomodulatory drug. Requirements include BCMA expression, adequate organ function, and reasonable performance status. A free case review determines eligibility.
Which hospitals in China offer BCMA CAR-T for multiple myeloma?
Ruijin Hospital (Shanghai), Lu Daopei Hospital (Beijing), Fudan University Shanghai Cancer Center, and Tongji Hospital (Wuhan) are the top choices for international myeloma patients. All have international departments with English-speaking coordinators and visa support.
How long does CAR-T for multiple myeloma take, and is it safe?
4-6 weeks in China: apheresis (1 day) → manufacturing (2-4 weeks) → conditioning chemo (3-5 days) → infusion (1 day) → monitoring (10-14 days). Commercial products are NMPA-approved, and top centers manage CRS and neurotoxicity per international protocols with ICU support.
Get a Free Hospital Recommendation & Cost Estimate
Send us your latest bone marrow biopsy and treatment history — we'll check eligibility across commercial and trial routes, match you with 2-3 suitable hematology centers, and get written quotes. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review
Related Reading
- CAR-T Therapy for Lymphoma in China 2026
- CAR-T Therapy Cost in China 2026 (Full Price Guide)
- CAR-T Therapy Hospitals in China
- Cancer Treatment in China
- For Singapore patients: Guide to Treatment in China
- For Indonesian patients: Panduan Berobat di Tiongkok
- For Russian-speaking patients: лечение рака в Китае